Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study.

Casper W F van EijckDisha VadgamaCasper H J van EijckJohanna W Wilminknull null

Published in: Journal of the National Cancer Institute (2024)

This study unveils immune profile changes resulting from metformin use in upfront resected pancreatic cancer patients, possibly contributing to prolonged survival outcomes. Specifically, metformin use may decrease the abundance and activity of pro-tumoral M2 macrophages and increase the recruitment and function of tumor-resolving DCs, favoring antitumor immunity.[PREOPANC trial EudraCT: 2012-003181-40].

Keyphrases

lymph node
clinical trial
study protocol
prognostic factors
phase iii
anti inflammatory
antibiotic resistance genes
microbial community